• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Vaxxas licenses COVID-19 vaccine for patch delivery system, expects to finish Phase 1 trial this year

March 23, 2022 By Sean Whooley

Vaxxas micropatch vaccine COVID-19
Vaxxas’ patch comes in a hockey-puck-shaped applicator with a foil seal. [Image courtesy of Vaxxas]
Vaxxas announced today that it was granted an exclusive license for a next-generation COVID-19 vaccine to be used with its delivery patch.

Cambridge, Massachusetts-based Vaxxas received the license from The University of Texas at Austin for its HexaPro SARS-CoV-2 spike subunit vaccine. The license comes with a companion background technology license from the U.S. National Institutes of Health (NIH).

According to a news release, it enables Vaxxas to create the first needle-free, room-temperature, stable COVID-19 vaccine patch to enter clinical studies. PharmaJet is currently involved in clinical trials outside the U.S. for the delivery of a DNA vaccine with a needle-free platform.

In October 2020, Vaxxas received a $22 million award from the Biomedical Advanced Research and Development Authority (BARDA) at the U.S. Dept. of Health and Human Services (HHS) to support a clinical study for the patch.

UT Austin designed HexaPro as a highly stabilized protein that mimics the structure of the spike protein on the surface of the coronavirus to train the human immune system to recognize and fight SARS-CoV-2 infection. Preclinical studies demonstrated enhanced virus-neutralizing antibody and T-cell responses against all variants of concern, including alpha, beta, gamma, delta and omicron, when HexaPro was delivered with Vaxxas’ HD-MAP patch compared to needle and syringe vaccination.

Vaxxas plans to complete a Phase 1 clinical trial of the proprietary HexaPro/HD-MAP COVID-19 vaccine this year.

“The compelling preclinical results published in Science Advances established the potential superiority of the HD-MAP/HexaPro COVID-19 vaccine compared to delivery using the traditional needle and syringe,” Vaxxas President and CEO David Hoey said in the news release. “We can now rapidly advance our clinical trials with our next-generation COVID-19 vaccine patch.”

Filed Under: Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Preclinical Trials Tagged With: coronavirus, COVID-19, University of Texas at Austin, Vaxxas

IN CASE YOU MISSED IT

  • FDA lifts hold on Vertex’s insulin-producing cell therapy for diabetes
  • Retractable Technologies declares dividends
  • Teva appoints former Vertex exec as new head of R&D, CMO
  • West Pharmaceutical Services debuts new needle syringe system
  • CeQur is launching a discreet, convenient ‘wearable insulin pen’

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS